These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes. Kintscher U Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Cohen S; Sternlicht H; Bakris GL Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Marzolla V; Infante M; Armani A; Rizzo M; Caprio M Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659 [TBL] [Abstract][Full Text] [Related]
13. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis. Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348 [TBL] [Abstract][Full Text] [Related]
15. Role of mineralocorticoid receptor antagonists in kidney diseases. Patel V; Joharapurkar A; Jain M Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798 [TBL] [Abstract][Full Text] [Related]
16. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Gregg LP; Navaneethan SD Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349 [TBL] [Abstract][Full Text] [Related]
17. Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials. Saito R; Nakada T Drug Metab Pharmacokinet; 2024 Jun; 56():101019. PubMed ID: 38797092 [TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349 [TBL] [Abstract][Full Text] [Related]
19. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial. Haller H Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559 [TBL] [Abstract][Full Text] [Related]